Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Barclays Initiates Coverage On Celldex Therapeutics with Underweight Rating, Announces Price Target of $25

Author: Benzinga Newsdesk | October 13, 2025 08:17am

Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announces Price Target of $25.

Posted In: CLDX